Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.
| Added by | mollevi |
|---|---|
| Group name | EquipeMY |
| Item Type | Attachment |
| Title | 24407191 |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/24407191 |
| Accessed | 2018/05/23 - 14:16:31 |
| Date Added | 2019/05/22 - 09:42:41 |
| Date Modified | 2019/05/22 - 09:42:41 |
| Parent item | Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial |
Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).
U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de